Nk-1 receptor antagonists and eletriptan for the treatment...

Details Nk-1 receptor antagonists and eletriptan for the treatment... Nk-1 receptor antagonists and eletriptan for the treatment...

A - Human Necessities

61

K

A61K 31/4045 (2006.01) A61K 31/40 (2006.01) A61K 31/435 (2006.01) A61K 31/438 (2006.01) A61K 31/439 (2006.01) A61K 31/445 (2006.01) A61K 31/451 (2006.01) A61K 31/453 (2006.01) A61K 31/454 (2006.01) A61K 31/4709 (2006.01) A61K 31/535 (2006.01) A61K 31/5377 (2006.01) A61K 31/538 (2006.01) A61K 31/54 (2006.01) A61P 25/06 (2006.01)

Patent

CA 2324116

The present invention relates to a method of treating or preventing migraine in a mammal, including a human, by administering to the mammal eletriptan or a pharmaceutically acceptable salt of eletriptan and an NK-1 receptor antagonist (e.g., a substance P receptor antagonist). It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, eletriptan or a pharmaceutically acceptable salt of eletriptan and an NK-1 receptor antagonist.

Affiliated with

Also associated with

Rating

Nk-1 receptor antagonists and eletriptan for the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nk-1 receptor antagonists and eletriptan for the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nk-1 receptor antagonists and eletriptan for the treatment... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2030902